Cidara Therapeutics is a leading brand in the field of immunotherapy, offering a powerful new class of therapeutics designed to save lives and improve the standard of care for patients facing serious diseases. They have developed a proprietary technology platform that consists of highly potent, long-acting, drug-Fc conjugates (DFCs). These conjugates are designed to inhibit specific disease targets while simultaneously engaging the immune system, providing a more targeted and effective approach to treatment.

Cidara's pipeline includes therapeutics for a range of diseases, including immuno-oncology, influenza, SARS-CoV-2, and other viruses, as well as antifungal treatments. Their innovative approach holds great promise for patients in need of more effective and long-lasting therapies. Backed by a leadership team with extensive experience in the field, Cidara Therapeutics is dedicated to advancing the standard of care through their groundbreaking research and development.

With a focus on partnerships, publications, and expanding their pipeline, Cidara Therapeutics is at the forefront of transforming the treatment landscape for serious diseases